Eli Lilly and Company (LLY)
Eli Lilly and Company (LLY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Eli Lilly and Company (LLY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Is It Too Late To Buy The Rally In Eli Lilly Stock?
This article was written and reviewed by Doug Nathman and his team at Trefis. For questions, email [email protected].
Prediction: Eli Lilly Will Trade at This Price in a Year
Eli Lilly (NYSE:LLY | LLY Price Prediction) is finally acting like a trillion-dollar drugmaker again.
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs?
LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering strong weight-loss and diabetes results.
Eli Lilly stock rises as Retatrutide data boosts obesity drug lead
Shares of Eli Lilly LLY climbed about 4% on Monday after the drugmaker unveiled encouraging new clinical data for its next-generation obesity treatment, retatrutide. This has reinforced investor confidence in the company's long-term position in the rapidly expanding weight-loss market.
Is Trending Stock Eli Lilly and Company (LLY) a Buy Now?
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug
Eli Lilly shares jumped in premarket trade on Monday, after a late-stage trial of its next-generation weight-loss drug impressed analysts.
Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year
The seasonal strength lines up with major medical and scientific conferences that cluster during this period.
LLY Rises 14% in a Month: Should You Hold as Obesity Growth Continues?
Eli Lilly stock gains 14% in a month as strong Q1 results, obesity drug coverage expansion and promising retatrutide data fueled momentum.
Where Will Eli Lilly Stock be In 2028?
Eli Lilly (NYSE:LLY | LLY Price Prediction) just grew revenue 55.5% in a single quarter while raising full-year guidance to $82 billion to $85 billion.
LLY Stock Gains 4% to All-Time High: Is Obesity Access the Catalyst?
Eli Lilly hits a record high after CVS expands coverage for Foundayo and Zepbound, boosting obesity drug access and raising the stakes in its rivalry with NVO.
Eli Lilly and Company (LLY) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Eli Lilly and Company (LLY) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
